289 related articles for article (PubMed ID: 16390761)
1. Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs.
Werner HM; Franke HR; Vermes I
Climacteric; 2005 Sep; 8(3):294-9. PubMed ID: 16390761
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells.
Seeger H; Rakov V; Mueck AO
Horm Metab Res; 2005 Aug; 37(8):468-73. PubMed ID: 16138258
[TBL] [Abstract][Full Text] [Related]
3. Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Jansen GH; Franke HR; Wolbers F; Brinkhuis M; Vermes I
Climacteric; 2008 Aug; 11(4):315-21. PubMed ID: 18645697
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.
Mueck AO; Seeger H; Wallwiener D
Climacteric; 2003 Sep; 6(3):221-7. PubMed ID: 14567770
[TBL] [Abstract][Full Text] [Related]
5. The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor- and estradiol-treated human cancerous and noncancerous breast cells.
Krämer EA; Seeger H; Krämer B; Wallwiener D; Mueck AO
Menopause; 2005; 12(4):468-74. PubMed ID: 16037763
[TBL] [Abstract][Full Text] [Related]
6. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells.
Mirkin S; Wong BC; Archer DF
Fertil Steril; 2005 Aug; 84(2):485-91. PubMed ID: 16084894
[TBL] [Abstract][Full Text] [Related]
7. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
[TBL] [Abstract][Full Text] [Related]
8. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
[TBL] [Abstract][Full Text] [Related]
9. Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells.
Gao ZO; Gao ZP; Fields JZ; Boman BM
Anticancer Res; 2002; 22(3):1379-83. PubMed ID: 12168814
[TBL] [Abstract][Full Text] [Related]
10. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
Power KA; Thompson LU
Breast Cancer Res Treat; 2003 Oct; 81(3):209-21. PubMed ID: 14620916
[TBL] [Abstract][Full Text] [Related]
11. Growth response of colon cancer cell lines to selective estrogen receptor modulators.
Picariello L; Fiorelli G; Martineti V; Tognarini I; Pampaloni B; Tonelli F; Brandi ML
Anticancer Res; 2003; 23(3B):2419-24. PubMed ID: 12894523
[TBL] [Abstract][Full Text] [Related]
12. The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells.
Seeger H; Wallwiener D; Mueck AO
Horm Metab Res; 2003 Feb; 35(2):76-80. PubMed ID: 12734785
[TBL] [Abstract][Full Text] [Related]
13. Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis.
Seeger H; Wallwiener D; Mueck AO
Gynecol Endocrinol; 2008 Oct; 24(10):576-9. PubMed ID: 19012101
[TBL] [Abstract][Full Text] [Related]
14. Effects of estradiol and progestogens on human breast cells: regulation of sex steroid receptors.
Chen FP; Chien MH; Chen HY; Huang TS; Ng YT
Taiwan J Obstet Gynecol; 2013 Sep; 52(3):365-73. PubMed ID: 24075375
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
Levenson AS; Svoboda KM; Pease KM; Kaiser SA; Chen B; Simons LA; Jovanovic BD; Dyck PA; Jordan VC
Cancer Res; 2002 Aug; 62(15):4419-26. PubMed ID: 12154049
[TBL] [Abstract][Full Text] [Related]
16. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells.
Neubauer H; Yang Y; Seeger H; Fehm T; Cahill MA; Tong X; Ruan X; Mueck AO
Menopause; 2011 Aug; 18(8):845-50. PubMed ID: 21532513
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells.
Xu B; Kitawaki J; Koshiba H; Ishihara H; Kiyomizu M; Teramoto M; Kitaoka Y; Honjo H
Maturitas; 2007 Feb; 56(2):142-52. PubMed ID: 16962266
[TBL] [Abstract][Full Text] [Related]
18. Effects of tibolone and its metabolites on Angiopoietin-1, Tie-2 and tumor necrosis factor-alpha mRNA in Ishikawa cells. Implication for tibolone's effects on the endometrium.
Mirkin S; Archer DF
Maturitas; 2007 Aug; 57(4):338-46. PubMed ID: 17478063
[TBL] [Abstract][Full Text] [Related]
19. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model.
Bläuer M; Heinonen PK; Rovio P; Ylikomi T
Eur J Pharmacol; 2008 Sep; 592(1-3):13-8. PubMed ID: 18638473
[TBL] [Abstract][Full Text] [Related]
20. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
